This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2022
ASCO GU 2022
Prostate Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO GU 2022 Prostate Cancer
Viewing 41-60 of 172 articles
ASCO GU 2022: Predictive Factors for Effectiveness from Novel Androgen-Receptor-Axis-Targeted Agents in Patients with Metastatic Prostate Cancer
ASCO GU 2022: Correlation of the Rate of Metastasis-Free Survival with the Presence of Pathogenic Germline Genetic Mutations in Patients with Prostate Cancer at a Community Practice
ASCO GU 2022: PEARLS: A Multicenter Phase II/III Trial of Extended Field Radiotherapy for Androgen Sensitive Prostate Cancer Patients with PSMA‐avid Pelvic and Para-Aortic Lymph Nodes at Presentation
ASCO GU 2022: Dual-Tracer PET/CT-Targeted, mpMRI-Targeted, Systematic Biopsy, and Combined Biopsy for the Diagnosis of Prostate Cancer
ASCO GU 2022: Do Prostate MRI Reports Consider Focal Therapy When Describing Diagnostic Findings? a Descriptive Review and Analysis of Concordance Among Prostate MRI Reports and Radical Prostatectomy Pathology Reports
ASCO GU 2022: Development and Validation of a Prognostic AI Biomarker Using Multi-Modal Deep Learning with Digital Histopathology in Localized Prostate Cancer on NRG Oncology Phase III Clinical Trials
ASCO GU 2022: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP1801)
ASCO GU 2022: Optimizing Management of Localized Prostate Cancer: Combined Modality Therapy in Localized Disease
ASCO GU 2022: Attainment of Early, Deep PSA Response in mCSPC: A Comparison of Patients Initiated on Apalutamide or Enzalutamide
ASCO GU 2022: Association of Functional Outcomes by Decision-Making Approach in Men with Metastatic Prostate Cancer
ASCO GU 2022: Artificial Intelligence as a Disruptive Technology in Medicine
ASCO GU 2022: An AI-Derived Digital Pathology-Based Biomarker to Predict the Benefit of ADT in Localized Prostate Cancer with Validation in NRG/RTOG 9408
ASCO GU 2022: 68Ga-PSMA PET/CT for Preoperative Lymph Nodes Staging of High-Risk Prostate Cancer
ASCO GU 2022: A Phase Ia/Ib Study of Talazoparib in Combination with Tazemetostat in mCRPC
ASCO GU 2022: Active Surveillance for Patients with Intermediate-Risk Disease: Risk vs. Benefit
ASCO GU 2022: Treatment Trends Among Men With Metastatic Castration Sensitive Prostate Cancer: Results From the US Component of an International Study
ASCO GU 2022: Impact of Provider Education on Prostate Cancer Genetic Counseling Referrals
ASCO GU 2022: A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2022: Characteristics of Prostate Cancer Survivors Exposed to ADT and Enrolled in a Fall Prevention Exercise Trial: Comparison of Men With Confirmed Fall History to Men With Fall Risk Factors
ASCO GU 2022: DS-7300 (B7-H3 DXd-ADC) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Subgroup Analysis of a Phase 1/2 Multicenter Study
1
2
3
4
5
6
7
8
9
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free